GENE ONLINE|News &
Opinion
Blog

Hepatocellular Carcinoma
AstraZeneca’s Imfinzi, Tremelimumab Combo Significantly Improves Overall Survival in Phase 3 Trials
2021-10-18
uniQure’s Inquiry Shows Hemophilia B Gene Therapy not Likely to Have Induced Liver Cancer
2021-03-30
CRISPR-Based Screening Implicates Mitochondrial Phosphatase Gene in Hypoxic Survival of Liver Cancer Cells
2021-02-03
uniQure’s Hemophilia B Gene Therapy Put on Clinical Hold by the FDA
2020-12-22
China’s Regulatory Body Accepts Application for First Selective Internal Radiation Therapy for HCC
2020-11-29
Roche’s Elecsys GALAD Score that Predicts HCC Occurrence, Bags Breakthrough Designation
2020-03-06
ESMO Asia 2019 Roundup
2019-12-10
New hepatocellular carcinoma approval for Pembrolizumab – KN-224
2018-11-14
Singapore HSA approves phase I/II clinical trial for precision T-cell receptor immunotherapy
2018-09-14
November 8, 2012: Completion of the Liver Cancer Genome
2017-11-07
LATEST
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
Exosomes: The Small Couriers Moving Beyond Traditional Drug Delivery
2025-04-17
Trump Administration’s CDC Layoffs Shutter STD Lab, Sending Ripples Through Biotech and Global Health
2025-04-17
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
NIH Facing $20 Billion Budget Cut and Potential Consolidation in 2026
2025-04-16
Trump Administration Budget Proposal Includes $20 Billion Cut to NIH by 2026 and Agency Reorganization
2025-04-16
Robert F. Kennedy Jr.’s Proposed Budget Prioritizes Public Health, Environmental Protection, and Healthcare Reform
2025-04-16
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top